On Employee Appreciation Day, we wanted to thank our amazing team. With your Lone Star grit, your work is making a difference for patients with fibrosis. We appreciate your valuable contributions whether you’re behind the scenes or in the spotlight. Your dedication and commitment to our mission inspires us all. We are proud to have such talent, dedication and passion that you bring every day. Our work doesn’t stop until we rein in fibrosis! #EmployeeAppreciation #Fibrosis #IPF
Rein Therapeutics
生物技术研究
Austin，Texas 7,582 位关注者
Developing novel medicines to provide better treatment options for patients with life-threatening pulmonary conditions.
关于我们
Rein Therapeutics is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Rein's lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is anticipated to initiate a Phase 2 clinical trial in the first half of 2025 for the treatment of idiopathic pulmonary fibrosis. Rein’s second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the U.S. and E.U. and Fast Track Designation in the U.S. For more information, please visit www.reintx.com or follow us on Twitter at @Rein_Tx.
- 网站
-
https://reintx.com
Rein Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Austin，Texas
- 类型
- 上市公司
- 创立
- 2025
- 领域
- Drug Development、Biopharmaceuticals、Fibrosis和Pulmonary
地点
-
主要
获取路线
12407 N Mo Pac Expy
390
US，Texas，Austin，78758
Rein Therapeutics员工
动态
-
I am attending BIO-Europe Spring in Milan from March 17-19. I look forward to connecting with other life sciences industry leaders and expanding our network. If you would like to meet to learn more about our multi-pathway treatments for fibrosis, please email [email protected] #Fibrosis #LifeSciences #Biotech #BIOEuropeSpring
-
-
Loculated Pleural Effusion (LPE) occurs when fibrotic scar tissue forms in the pleural cavity, preventing effective drainage of fluid. ? LTI-01 is the first therapy specifically developed for the treatment of non-draining LPE and received Orphan Drug Designation for the treatment of pleural empyema in the U.S. and E.U. ? For #RareDiseaseDay, we want to highlight our commitment to finding a better treatment option for people living with LPE and any of the related complications from the disease. ? #LPE #OrphanDrug
-
-
On International Day of Women and Girls in Science, we’re proud to recognize the talented women on our team who bring fresh perspectives, energy, and innovation to the STEM field. Their dedication and expertise play a critical role in our mission to rein in fibrosis, pushing the boundaries of discovery and progress. ? We’re grateful for their invaluable contributions and Rein is committed to fostering an environment where women in science thrive. ? Here’s to inspiring the next generation of trailblazers! ? #WomenInScience #STEM #InternationalDayOfWomenAndGirlsInScience #Innovation #WomenInSTEM #February11
-
Follow along for a series of articles that aim to educate and dive deeper into Idiopathic Pulmonary Fibrosis (IPF)! #IPF #LungHealth #Biotech #Healthcare #Research
-
Today, we introduced our new name, Rein Therapeutics, a new chapter in our journey to dramatically improve patients’ lives. Our work doesn’t stop until we end fibrosis! Shares will begin trading under our new ticker symbol “RNTX” on January 13, 2025. Follow us on X at @Rein_Tx or visit our new website at www.reintx.com Read more about the re-brand here: https://bit.ly/4h8RxFQ #fibrosis #IPF #LPE
-
We announced positive topline data from Cohort 2 of the Phase 1b study evaluating LTI-03 in patients diagnosed with IPF. Read our data here: https://bit.ly/3O722g9 ? We also held a call featuring IPF key opinion leader and study investigator, Prof. Andreas Gunther, M.D., Head of the Center for Interstitial and Rare Lung Diseases of the Justus Liebig University in Giessen, Germany. A replay is available here: https://bit.ly/4erACMV ? #IPF
-